TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20339140

Group type: EXPERIMENTAL
Intervention: Long-acting octreotide acetate (LAO) 30 mg via intramuscular injection, given 4-7 days before radiation and on day 22 of treatment.
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo, given 4-7 days before radiation and on day 22 of treatment.
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Long-acting octreotide acetate (LAO)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 17592288

Group type: EXPERIMENTAL
Intervention: Enteral nutrition supplemented with a composition of 4 Lactobacillus (LAB) and 4 fibers
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (fibers only)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Enteral nutrition supplemented with a composition of 4 LAB and 4 fibers
Number of subjects: 80
Study: 16125941

Group type: EXPERIMENTAL
Intervention: Mobile polyethylene bearing
Number of subjects: 52

Group type: COMPARATOR
Intervention: Fixed polyethylene bearing
Number of subjects: 52
Study: 15323164

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (at least one course)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 48
Study: 10525558

Group type: EXPERIMENTAL
Intervention: salmeterol
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: salmeterol + ipratropium bromide
Number of subjects: 144

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 144
Study: 8675251

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High insulinemia (287 pmol/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basal conditions
Number of subjects: 0
Study: 1999687

Group type: EXPERIMENTAL
Intervention: Beta-carotene (10 mg daily for 3 months)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Total intake of beta-carotene (diet + medication)
Number of subjects: 278
Study: 6095660

Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg taken orally at night for 12 months
Number of subjects: 454

Group type: COMPARATOR
Intervention: cimetidine 400 mg taken orally at night for 12 months
Number of subjects: 454
Study: 29766378

Group type: EXPERIMENTAL
Intervention: 5% MPC‐polymer mouthwash
Number of subjects: 20

Group type: COMPARATOR
Intervention: PBS (placebo)
Number of subjects: 20
Study: 27686820

Group type: COMPARATOR
Intervention: Acute milk intake
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Chronic milk intake
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fruit-juice (control for acute experiment)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fruit-juice (control for chronic experiment)
Number of subjects: 28
Study: 26362664

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study: 23318242

Group type: EXPERIMENTAL
Intervention: Group-based Parent Management Training (PMTO, 12 sessions)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 137
Study: 21996070

Group type: EXPERIMENTAL
Intervention: Computer kiosk-expedited management
Number of subjects: 624

Group type: COMPARATOR
Intervention: Usual ED care
Number of subjects: 624
Study: 20021458

Group type: EXPERIMENTAL
Intervention: Screening programs for asbestos-exposed individuals involving annual pulmonary function tests, chest radiography, and high-resolution computer tomography.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene and protein expression studies aimed at identifying clinically useful biomarkers and new therapeutic targets.
Number of subjects: 0
Study: 17511784

Group type: EXPERIMENTAL
Intervention: ProFile .04
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GT Rotary
Number of subjects: 50
Study: 15338805

Group type: EXPERIMENTAL
Intervention: 250 mg of testosterone, intra-muscularly, every fourth week for 26 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 12562110

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 9613016

Group type: EXPERIMENTAL
Intervention: Negative appraisal condition (safety behaviors employed)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Positive appraisal condition (safety behaviors not employed)
Number of subjects: 82
Study: 8277078

Group type: EXPERIMENTAL
Intervention: SHU 508A (200 mg/ml in 5 ml, 200 mg/ml in 10 ml, 300 mg/ml in 5 ml, 300 mg/ml in 10 ml)
Number of subjects: 35
Study: 2551411

Group type: EXPERIMENTAL
Intervention: Fish oil (5.4 g eicosapentaenoic acid and 3.6 g docosahexaenoic acid)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vegetable oil (control)
Number of subjects: 8
Study: 786670

Group type: EXPERIMENTAL
Intervention: Nomifensin (average daily dose 84 mg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Desimipramine (average daily dose 76 mg)
Number of subjects: 43
Study: 31599847

Group type: EXPERIMENTAL
Intervention: Bremelanotide
Number of subjects: 856

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 856
Study: 29308523

Group type: EXPERIMENTAL
Intervention: 100 g-force
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 150 g-force
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 200 g-force
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study: 26153058

Group type: EXPERIMENTAL
Intervention: Standard rehabilitation plus intervention (IG)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard rehabilitation (CG)
Number of subjects: 112
Study: 23668634

Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE) 20 mg, 50 mg, 150 mg, 500 mg, or 1000 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE) 50 mg and 500 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE)
Number of subjects: 16
Study: 20855554

Group type: EXPERIMENTAL
Intervention: Shockwave therapy (SWT) - 2500 impulses per session at 0.18 mJ/mm² energy flux density for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional conservative treatment (TCT) - nonsteroidal anti-inflammatory drugs, physiotherapy, and an exercise program for hamstring muscles for 4 weeks
Number of subjects: 40
Study: 19333797

Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 68
Study: 17766923

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily for 6 months
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Metformin in obese women
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 56
Study: 15573333

Group type: EXPERIMENTAL
Intervention: Mutual goal setting nursing intervention
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Supportive-educative nursing interventions
Number of subjects: 88
Study: 11137806

Group type: EXPERIMENTAL
Intervention: Preoperative lipid control with simvastatin (group 2)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Patients with cholesterol <4.7mmol/l (group 3)
Number of subjects: 3
Study: 9505749

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (5 ml infiltrated along the scrotal incision and 1 ml injected into the vas deferens)
Number of subjects: 42
Study: 7881986

Group type: EXPERIMENTAL
Intervention: Iron supplementation (oral or intravenous)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring of iron status (serum ferritin and transferrin saturation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percentage of hypochromic erythrocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other methods (erythrocyte ferritin, free erythrocyte protoporphyrin, erythrocyte zinc protoporphyrin levels)
Number of subjects: 0
Study: 2119396

Group type: EXPERIMENTAL
Intervention: Sprinkle capsules
Number of subjects: 21

Group type: COMPARATOR
Intervention: Enteric-coated tablets
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sprinkle capsules (fasting)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enteric-coated tablets (fasting)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sprinkle capsules (nonfasting)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Food intake
Number of subjects: 21
Study: 322267

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid 600 mg administered as three divided doses with meals for one week.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Acetylsalicylic acid 3 g administered as three divided doses with meals for one week.
Number of subjects: 10
Study: 30770596

Group type: EXPERIMENTAL
Intervention: Intra-laboratory analysis in Wurzburg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intra-laboratory analysis in Bologna
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Inter-laboratory analysis
Number of subjects: 43
Study: 28618170

Group type: EXPERIMENTAL
Intervention: Dietary intervention (four diets varying in macronutrient content)
Number of subjects: 367
Study: 24925672

Group type: EXPERIMENTAL
Intervention: Post‐trochanteric groove support
Number of subjects: 10

Group type: COMPARATOR
Intervention: No post‐trochanteric groove support
Number of subjects: 10
Study: 23471944

Group type: EXPERIMENTAL
Intervention: 4 kcal·kg body wt(‐1)·wk(‐1) aerobic training
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: 8 kcal·kg body wt(‐1)·wk(‐1) aerobic training
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: 12 kcal·kg body wt(‐1)·wk(‐1) aerobic training
Number of subjects: 386

Group type: COMPARATOR
Intervention: All exercise groups
Number of subjects: 386
Study: 21690032

Group type: EXPERIMENTAL
Intervention: Semantic training with examples from musical instrument category
Number of subjects: 10

Group type: COMPARATOR
Intervention: Psychological support (Control)
Number of subjects: 10
Study: 19786433

Group type: EXPERIMENTAL
Intervention: Parents estimating blood loss
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Nurses estimating blood loss
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Doctors estimating blood loss
Number of subjects: 227
Study: 17559759

Group type: COMPARATOR
Intervention: Chevron osteotomy
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Scarf osteotomy
Number of subjects: 83
Study: 15596577

Group type: EXPERIMENTAL
Intervention: Rigid gas‐permeable contact lenses (RGPs)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Soft contact lenses (SCLs)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Rigid gas‐permeable contact lenses (RGPs) and Soft contact lenses (SCLs)
Number of subjects: 116
Study: 11152249

Group type: EXPERIMENTAL
Intervention: 100% oxygen (4 L min(‐1))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Air (21% oxygen, 4 L min(‐1))
Number of subjects: 16
Study: 9091710

Group type: EXPERIMENTAL
Intervention: Oxybuprocaine sponge anesthesia
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Oxybuprocaine sponge anesthesia with tramadol
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Retrobulbar injection (prilocaine/etidocaine mixture)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Retrobulbar injection
Number of subjects: 150
Study: 1301126

Group type: EXPERIMENTAL
Intervention: Rehabilitation programme (R)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Hospital-based treatment (H)
Number of subjects: 205
Study: 3905773

Group type: EXPERIMENTAL
Intervention: Methylphenidate (up to 60 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30372126

Group type: EXPERIMENTAL
Intervention: MOP 4-week maxilla/8-week mandible (n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MOP 8-week maxilla/12-week mandible (n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MOP 12-week maxilla/4-week mandible (n=10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (non-MOP sites)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MOP (overall)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pain associated with MOP
Number of subjects: 30
Study: 29699021

Group type: EXPERIMENTAL
Intervention: Ulinastatin 100,000 u intravenous injection every 8 hours for 7 days
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group treated with hyperbaric oxygen and routine medical treatment
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Ulinastatin treatment
Number of subjects: 123
Study: 26873242

Group type: EXPERIMENTAL
Intervention: Vitamin D (300,000 IU, IM)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 24444545

Group type: EXPERIMENTAL
Intervention: MED on/DBS on
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MED on/DBS off
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MED off/DBS on
Number of subjects: 18

Group type: COMPARATOR
Intervention: MED off/DBS off
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DBS on
Number of subjects: 18

Group type: COMPARATOR
Intervention: DBS off
Number of subjects: 18
Study: 23183990

Group type: EXPERIMENTAL
Intervention: Multimodal treatment program
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (verbal or written information)
Number of subjects: 800
Study: 19237997

Group type: EXPERIMENTAL
Intervention: Physical Activity on Prescription (PAP)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Minimal intervention (Control)
Number of subjects: 101
Study: 17785618

Group type: EXPERIMENTAL
Intervention: Sildenafil (25 to 75 mg orally 3 times daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 34
Study: 15932791

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg four times a day
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 11936711

Group type: EXPERIMENTAL
Intervention: Multi-speciality team intervention
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 157
Study: 9616263

Group type: EXPERIMENTAL
Intervention: NaHCO3 (metabolic alkalosis)
Number of subjects: 8

Group type: COMPARATOR
Intervention: NaCl
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NH4Cl (metabolic acidosis)
Number of subjects: 8
Study: 8732147

Group type: EXPERIMENTAL
Intervention: Taponin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 45
Study: 2495337

Group type: EXPERIMENTAL
Intervention: Physician reminder message
Number of subjects: 1587

Group type: EXPERIMENTAL
Intervention: Letter sent to patients
Number of subjects: 1587

Group type: EXPERIMENTAL
Intervention: Telephone call from practice nurse
Number of subjects: 1587

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1587
Study: 17557

Group type: EXPERIMENTAL
Intervention: Penbutolol (8 mg to 50 mg per day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 30222051

Group type: EXPERIMENTAL
Intervention: Invited group (household-based prospective cohort study)
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Uninvited, non-contacted control group
Number of subjects: 20000
Study: 30560527

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 45

Group type: COMPARATOR
Intervention: Antibiotic therapy
Number of subjects: 45
Study: 27837709

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) including medication assessment annually between 2004 and 2007
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (no CGA)
Number of subjects: 1000
Study: 25602358

Group type: EXPERIMENTAL
Intervention: Protocolized sedation (intervention group, n = 1225 patients)
Number of subjects: 2449

Group type: COMPARATOR
Intervention: Usual care (control group, n = 1224 patients)
Number of subjects: 2449

Group type: EXPERIMENTAL
Intervention: Protocolized sedation
Number of subjects: 2449
Study: 23376894

Group type: EXPERIMENTAL
Intervention: MiSight contact lenses
Number of subjects: 24

Group type: COMPARATOR
Intervention: Proclear Multifocal +2.00 diopters Add D (MF) soft contact lenses
Number of subjects: 24
Study: 20471706

Group type: EXPERIMENTAL
Intervention: Digoxin treatment
Number of subjects: 938
Study: 19480865

Group type: EXPERIMENTAL
Intervention: Combined use of inspiratory and expiratory devices, training group (16 patients)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham training control group (16 patients)
Number of subjects: 32
Study: 17064903

Group type: EXPERIMENTAL
Intervention: Reaching within arm's length
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reaching beyond arm's length
Number of subjects: 0

Group type: COMPARATOR
Intervention: Movement velocity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Final joint configuration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Center of mass analysis during reaching
Number of subjects: 0
Study: 15157793

Group type: EXPERIMENTAL
Intervention: Preabortion counseling (intervention group)
Number of subjects: 420

Group type: COMPARATOR
Intervention: No preabortion counseling (control group)
Number of subjects: 420
Study: 10769857

Group type: EXPERIMENTAL
Intervention: 50% N2O/O2
Number of subjects: 19

Group type: COMPARATOR
Intervention: 100% O2
Number of subjects: 19
Study: 9314793

Group type: EXPERIMENTAL
Intervention: CPR with social support intervention
Number of subjects: 337

Group type: COMPARATOR
Intervention: Control
Number of subjects: 337

Group type: COMPARATOR
Intervention: CPR only
Number of subjects: 337

Group type: COMPARATOR
Intervention: CPR with cardiac risk factor education
Number of subjects: 337
Study: 8154254

Group type: EXPERIMENTAL
Intervention: Lidocaine with adrenaline, bupivacaine with adrenaline, and hyaluronidase
Number of subjects: 139

Group type: COMPARATOR
Intervention: Other tested mixtures (without hyaluronidase)
Number of subjects: 139
Study: 3538753

Group type: EXPERIMENTAL
Intervention: Femoxetine (200 mg increasing to 600 mg daily over 9 days)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Femoxetine
Number of subjects: 65
Study: 30031787

Group type: EXPERIMENTAL
Intervention: Food insecurity during both periods (prenatal and infancy)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Prenatal food insecurity
Number of subjects: 412
Study: 28532406

Group type: EXPERIMENTAL
Intervention: Vildagliptin/Metformin therapy (n = 40)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metformin alone (n = 20)
Number of subjects: 60
Study: 27128001

Group type: EXPERIMENTAL
Intervention: Ketoconazole (strong CYP3A4 inhibitor)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Azithromycin (weak CYP3A4 inhibitor)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Rifampin (CYP3A4 inducer)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Alisporivir (as an inhibitor of CYP3A4)
Number of subjects: 3
Study: 23997106

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg)
Number of subjects: 12
Study: 21146637

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Aspirin placebo
Number of subjects: 92

Group type: COMPARATOR
Intervention: Simvastatin placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Aspirin and Simvastatin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 92
Study: 19064627

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine
Number of subjects: 894

Group type: COMPARATOR
Intervention: Rabies vaccine
Number of subjects: 894
Study: 16934158

Group type: EXPERIMENTAL
Intervention: Fixed-dose artesunate-sulfamethoxypyrazine-pyrimethamine (AS+SMP f) administered at 12-hour intervals for 24 hours
Number of subjects: 73

Group type: COMPARATOR
Intervention: Loose combination of artesunate-sulfamethoxypyrazine-pyrimethamine (AS+SMP l) administered at 24-hour intervals for 3 days
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both regimens (AS+SMP f and AS+SMP l)
Number of subjects: 73
Study: 12663967

Group type: EXPERIMENTAL
Intervention: Talent LPS stent graft
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard surgical repair
Number of subjects: 240
Study: 10633973

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day for one week and 40 mg/day thereafter (group I)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day (group II)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Fluoxetine (group I)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sertraline (group II)
Number of subjects: 57
Study: 8607401

Group type: EXPERIMENTAL
Intervention: Quinapril (5 to 10 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metoprolol (50 to 100 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Quinapril and Metoprolol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Post-myocardial infarction patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 60
Study: 1901181

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Isosorbide dinitrate tablets
Number of subjects: 100
Study: 7083734

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (50 mg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Aspirin (650 mg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 30586694

Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg once daily for 16 weeks
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Macitentan
Number of subjects: 226
Study: 28765326

Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) monotherapy (75 mg/m2 × 7 days every 28 days)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Azacitidine (AZA) combined with Vorinostat (VOR) (300 mg twice a day on days 3 to 9)
Number of subjects: 259